+

WO2002018335A1 - Derives d'amine cyclique - Google Patents

Derives d'amine cyclique Download PDF

Info

Publication number
WO2002018335A1
WO2002018335A1 PCT/JP2001/007321 JP0107321W WO0218335A1 WO 2002018335 A1 WO2002018335 A1 WO 2002018335A1 JP 0107321 W JP0107321 W JP 0107321W WO 0218335 A1 WO0218335 A1 WO 0218335A1
Authority
WO
WIPO (PCT)
Prior art keywords
cyclic amine
amine derivatives
optionally substituted
group
ccr3
Prior art date
Application number
PCT/JP2001/007321
Other languages
English (en)
Japanese (ja)
Inventor
Koichiro Morihira
Hiroshi Inami
Hirokazu Kubota
Kazuhiro Yokoyama
Tatsuaki Morokata
Makoto Takeuchi
Toshiya Takahashi
Masayuki Kaneko
Takayuki Imaoka
Yuichi Torii
Yosuke Iura
Original Assignee
Yamanouchi Pharmaceutical Co., Ltd.
Toray Industries, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yamanouchi Pharmaceutical Co., Ltd., Toray Industries, Inc. filed Critical Yamanouchi Pharmaceutical Co., Ltd.
Priority to AU2001280187A priority Critical patent/AU2001280187A1/en
Publication of WO2002018335A1 publication Critical patent/WO2002018335A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des dérivés saturés d'amine cyclique comportant chacun un groupe -CH2-D sur l'atome d'azote et un groupe spécifique contenant un carbocycle ou un hétérocycle sur l'un des atomes de carbone, ou des sels desdits composés (D étant aryle éventuellement substitué, un groupe hétérocyclique éventuellement substitué ou cycloalkyle éventuellement substitué). Ces composés sont utiles dans le traitement de maladies associées à CCR3.
PCT/JP2001/007321 2000-08-28 2001-08-27 Derives d'amine cyclique WO2002018335A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001280187A AU2001280187A1 (en) 2000-08-28 2001-08-27 Cyclic amine derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2000-257451 2000-08-28
JP2000257451 2000-08-28

Publications (1)

Publication Number Publication Date
WO2002018335A1 true WO2002018335A1 (fr) 2002-03-07

Family

ID=18745906

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2001/007321 WO2002018335A1 (fr) 2000-08-28 2001-08-27 Derives d'amine cyclique

Country Status (2)

Country Link
AU (1) AU2001280187A1 (fr)
WO (1) WO2002018335A1 (fr)

Cited By (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003089418A1 (fr) * 2002-04-16 2003-10-30 Bayer Pharmaceuticals Corporation Derives indane de l'acide acetique et leur utilisation comme agents pharmaceutiques
WO2004022535A1 (fr) * 2002-08-28 2004-03-18 Yamanouchi Pharmaceutical Co., Ltd. Derives d'acrylamide
WO2004045518A3 (fr) * 2002-11-15 2004-10-07 Bristol Myers Squibb Co Modulateurs lies a prolyl uree a chaine ouverte de la fonction du recepteur d'androgene
FR2854158A1 (fr) * 2003-04-25 2004-10-29 Sanofi Synthelabo Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
WO2004054581A3 (fr) * 2002-12-13 2005-02-03 Smithkline Beecham Corp Composes de cyclohexyle utiles en tant qu'antagonistes du ccr5
US6919356B2 (en) 2002-09-26 2005-07-19 Bristol Myers Squibb Company N-substituted heterocyclic amines as modulators of chemokine receptor activity
WO2005033102A3 (fr) * 2003-10-03 2005-07-28 Amphora Discovery Corp Composes a base de thiophene presentant une activite d'inhibition d'enzymes utilisant l'atp, compositions contenant ces composes et utilisations
WO2005108359A1 (fr) * 2004-05-06 2005-11-17 Pfizer Inc. Nouveaux composes de derives de proline et de morpholine
WO2006028284A1 (fr) 2004-09-08 2006-03-16 Mitsubishi Pharma Corporation Dérivé de morpholine
JP2006514926A (ja) * 2002-11-12 2006-05-18 アボット・ラボラトリーズ ヒスタミン−３受容体リガンドとしての２環式置換アミン
US7186718B2 (en) 2001-08-22 2007-03-06 Astrazeneca Ab Piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity
US7196106B2 (en) 2002-11-05 2007-03-27 Merck & Co., Inc Cyanothiophene derivatives, compositions containing such compounds and methods of use
US7238691B2 (en) 2001-09-18 2007-07-03 Astrazeneca Ab Piperidine derivatives and their use as modulators of chemokine (especially CCR3) activity
US7279493B2 (en) 2002-06-28 2007-10-09 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7291744B2 (en) 2003-11-13 2007-11-06 Bristol-Myers Squibb Company N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity
US7307090B2 (en) 2001-07-02 2007-12-11 Astrazeneca Ab Piperidine derivatives useful as modulators of chemokine receptor activity
WO2008011392A3 (fr) * 2006-07-20 2008-05-22 Pharmacopeia Inc Antagonistes ccr1 de proline urée utilisés pour des maladies auto-immunes et l'inflammation
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7482363B2 (en) 2002-03-19 2009-01-27 Astrazeneca Ab Piperidine derivatives useful as modulators of chemokine receptor activity
WO2009016048A1 (fr) * 2007-07-27 2009-02-05 F. Hoffmann-La Roche Ag 2-azétidineméthaneamines et 2-pyrrolidineméthaneamines comme ligands de taar
US7495013B2 (en) 2003-04-01 2009-02-24 Astrazeneca Ab Chemical compounds
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
US7517989B2 (en) 2002-03-19 2009-04-14 Astrazeneca Ab Piperidine derivatives useful as modulators of chemokine receptor activity
US7541369B2 (en) 2002-03-13 2009-06-02 Janssen Pharmaceutica, Nv Amino-derivatives as novel inhibitors of histone deacetylase
US7576103B2 (en) 2004-12-21 2009-08-18 Roche Palo Alto Llc Tetralin and indane derivatives and uses thereof
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US20100197673A1 (en) * 2007-08-17 2010-08-05 Lg Life Sciences Ltd Indole and indazole compounds as an inhibitor of cellular necrosis
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
ES2350548A1 (es) * 2009-06-25 2011-01-25 Institut Univ. De Ciencia I Tecnologia, S.A. N-fenil-1-sulfonil-2-pirrolidinacarboxamidas para la identificacion de actividad biologica y farmacologica.
US8071615B2 (en) 2002-03-13 2011-12-06 Janssen Pharmaceutica N.V. Carbonylamino-derivatives as novel inhibitors of histone deacetylase
US8114876B2 (en) 2006-01-19 2012-02-14 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
US8314127B2 (en) 2005-07-21 2012-11-20 Astrazeneca Ab Piperidine derivatives
US8314107B2 (en) 2008-04-23 2012-11-20 Rigel Pharmaceuticals, Inc. Carboxamide compounds and methods for using the same
WO2014084330A1 (fr) * 2012-11-30 2014-06-05 協和発酵キリン株式会社 Composé hétérocyclique contenant de l'azote
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US9150543B2 (en) 2004-07-28 2015-10-06 Janssen Pharmaceutica N. V. Substituted indolyl alkyl amino derivatives as inhibitors of histone deacetylase
US9265734B2 (en) 2008-09-03 2016-02-23 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
US9540395B2 (en) 2011-02-28 2017-01-10 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US9663486B2 (en) 2013-10-14 2017-05-30 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
US10029988B2 (en) 2013-03-15 2018-07-24 Biomarin Pharmaceutical Inc. HDAC inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10087174B2 (en) 2013-10-14 2018-10-02 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
WO2019226490A1 (fr) * 2018-05-22 2019-11-28 Gilead Sciences, Inc. Dérivés sulfinylaminobenzamide et sulfonylaminobenzamide
US11267803B2 (en) 2016-06-21 2022-03-08 Orion Ophthalmology LLC Carbocyclic prolinamide derivatives
US11377439B2 (en) 2016-06-21 2022-07-05 Orion Ophthalmology LLC Heterocyclic prolinamide derivatives
US11618747B2 (en) 2018-06-28 2023-04-04 Orsobio, Inc. LXR modulators with bicyclic core moiety

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07505868A (ja) * 1992-03-31 1995-06-29 グラクソ、グループ、リミテッド 置換フェニルカルバメート類および尿素類
JPH08198751A (ja) * 1995-01-19 1996-08-06 Yamanouchi Pharmaceut Co Ltd カルバメート誘導体
WO2000076514A1 (fr) * 1999-06-11 2000-12-21 Merck & Co., Inc. Modulateurs de cyclopentyle de l'activite du recepteur de chimiokine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07505868A (ja) * 1992-03-31 1995-06-29 グラクソ、グループ、リミテッド 置換フェニルカルバメート類および尿素類
JPH08198751A (ja) * 1995-01-19 1996-08-06 Yamanouchi Pharmaceut Co Ltd カルバメート誘導体
WO2000076514A1 (fr) * 1999-06-11 2000-12-21 Merck & Co., Inc. Modulateurs de cyclopentyle de l'activite du recepteur de chimiokine

Cited By (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7307090B2 (en) 2001-07-02 2007-12-11 Astrazeneca Ab Piperidine derivatives useful as modulators of chemokine receptor activity
US7186718B2 (en) 2001-08-22 2007-03-06 Astrazeneca Ab Piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity
US7238691B2 (en) 2001-09-18 2007-07-03 Astrazeneca Ab Piperidine derivatives and their use as modulators of chemokine (especially CCR3) activity
US9150560B2 (en) 2002-03-13 2015-10-06 Janssen Pharmaceutica Nv Inhibitors of histone deacetylase
US8916554B2 (en) 2002-03-13 2014-12-23 Janssen Pharmaceutica, N.V. Amino-derivatives as novel inhibitors of histone deacetylase
US9533979B2 (en) 2002-03-13 2017-01-03 Janssen Pharmaceutica Nv Amino-derivatives as novel inhibitors of histone deacetylase
US8394831B2 (en) 2002-03-13 2013-03-12 Janssen Pharmaceutica, N.V. Carbonylamino-derivatives as novel inhibitors of histone deacetylase
US9556161B2 (en) 2002-03-13 2017-01-31 Janssen Pharmaceutica Nv Inhibitors of histone deacetylase
US8071615B2 (en) 2002-03-13 2011-12-06 Janssen Pharmaceutica N.V. Carbonylamino-derivatives as novel inhibitors of histone deacetylase
US7541369B2 (en) 2002-03-13 2009-06-02 Janssen Pharmaceutica, Nv Amino-derivatives as novel inhibitors of histone deacetylase
US7517989B2 (en) 2002-03-19 2009-04-14 Astrazeneca Ab Piperidine derivatives useful as modulators of chemokine receptor activity
US7482363B2 (en) 2002-03-19 2009-01-27 Astrazeneca Ab Piperidine derivatives useful as modulators of chemokine receptor activity
US7476742B2 (en) 2002-04-16 2009-01-13 Bayer Pharmaceuticals Corporation Indane acetic acid derivatives and their use as pharmaceutical agents
WO2003089418A1 (fr) * 2002-04-16 2003-10-30 Bayer Pharmaceuticals Corporation Derives indane de l'acide acetique et leur utilisation comme agents pharmaceutiques
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7279493B2 (en) 2002-06-28 2007-10-09 Euro-Celtique S.A. Therapeutic agents useful for treating pain
US7799786B2 (en) 2002-06-28 2010-09-21 Purdue Pharma L.P. Therapeutic agents useful for treating pain
WO2004022535A1 (fr) * 2002-08-28 2004-03-18 Yamanouchi Pharmaceutical Co., Ltd. Derives d'acrylamide
US6919356B2 (en) 2002-09-26 2005-07-19 Bristol Myers Squibb Company N-substituted heterocyclic amines as modulators of chemokine receptor activity
US7196106B2 (en) 2002-11-05 2007-03-27 Merck & Co., Inc Cyanothiophene derivatives, compositions containing such compounds and methods of use
JP4820094B2 (ja) * 2002-11-12 2011-11-24 アボット・ラボラトリーズ ヒスタミン−３受容体リガンドとしての２環式置換アミン
JP2006514926A (ja) * 2002-11-12 2006-05-18 アボット・ラボラトリーズ ヒスタミン−３受容体リガンドとしての２環式置換アミン
WO2004045518A3 (fr) * 2002-11-15 2004-10-07 Bristol Myers Squibb Co Modulateurs lies a prolyl uree a chaine ouverte de la fonction du recepteur d'androgene
US7632858B2 (en) 2002-11-15 2009-12-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
WO2004054581A3 (fr) * 2002-12-13 2005-02-03 Smithkline Beecham Corp Composes de cyclohexyle utiles en tant qu'antagonistes du ccr5
US7589207B2 (en) 2002-12-13 2009-09-15 Smithkline Beecham Corporation Cyclohexyl compounds as CCR5 antagonists
US7495013B2 (en) 2003-04-01 2009-02-24 Astrazeneca Ab Chemical compounds
FR2854158A1 (fr) * 2003-04-25 2004-10-29 Sanofi Synthelabo Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
RU2348630C2 (ru) * 2003-04-25 2009-03-10 Санофи-Авентис Производные 2-ациламино-4-фенилтиазола, их получение и их применение в терапии
US7504511B2 (en) 2003-04-25 2009-03-17 Sanofi-Aventis 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
WO2004096798A3 (fr) * 2003-04-25 2006-01-26 Sanofi Aventis Derives de 2-acylamino-4-phenylthiazole, leur preparation et leur application en therapeutique
US7777041B2 (en) 2003-04-25 2010-08-17 Sanofi-Aventis 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
US7504401B2 (en) 2003-08-29 2009-03-17 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
WO2005033102A3 (fr) * 2003-10-03 2005-07-28 Amphora Discovery Corp Composes a base de thiophene presentant une activite d'inhibition d'enzymes utilisant l'atp, compositions contenant ces composes et utilisations
US7291744B2 (en) 2003-11-13 2007-11-06 Bristol-Myers Squibb Company N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7989640B2 (en) 2004-02-04 2011-08-02 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
WO2005108359A1 (fr) * 2004-05-06 2005-11-17 Pfizer Inc. Nouveaux composes de derives de proline et de morpholine
US9636341B2 (en) 2004-07-28 2017-05-02 Janssen Pharmaceutica N.V. Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
US9150543B2 (en) 2004-07-28 2015-10-06 Janssen Pharmaceutica N. V. Substituted indolyl alkyl amino derivatives as inhibitors of histone deacetylase
WO2006028284A1 (fr) 2004-09-08 2006-03-16 Mitsubishi Pharma Corporation Dérivé de morpholine
US7576103B2 (en) 2004-12-21 2009-08-18 Roche Palo Alto Llc Tetralin and indane derivatives and uses thereof
US8314127B2 (en) 2005-07-21 2012-11-20 Astrazeneca Ab Piperidine derivatives
US9078896B2 (en) 2006-01-19 2015-07-14 Janssen Pharmaceutica, N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
US8114876B2 (en) 2006-01-19 2012-02-14 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
WO2008011392A3 (fr) * 2006-07-20 2008-05-22 Pharmacopeia Inc Antagonistes ccr1 de proline urée utilisés pour des maladies auto-immunes et l'inflammation
US8389507B2 (en) 2007-07-27 2013-03-05 Hoffmann-La Roche Inc. 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as TAAR-ligands
JP2010534701A (ja) * 2007-07-27 2010-11-11 エフ．ホフマン−ラ ロシュ アーゲー Ｔａａｒリガンドとしての２−アゼチジンメタンアミン及び２−ピロリジンメタンアミン
WO2009016048A1 (fr) * 2007-07-27 2009-02-05 F. Hoffmann-La Roche Ag 2-azétidineméthaneamines et 2-pyrrolidineméthaneamines comme ligands de taar
US20100197673A1 (en) * 2007-08-17 2010-08-05 Lg Life Sciences Ltd Indole and indazole compounds as an inhibitor of cellular necrosis
US8436038B2 (en) * 2007-08-17 2013-05-07 Lg Life Sciences Ltd. Indole and indazole compounds as an inhibitor of cellular necrosis
US9000028B2 (en) 2007-08-17 2015-04-07 Lg Life Sciences Ltd. Indole and indazole compounds as an inhibitor of cellular necrosis
US8785449B2 (en) 2008-04-23 2014-07-22 Rigel Pharmaceuticals, Inc. Carboxamide compounds and methods for using the same
US9353111B2 (en) 2008-04-23 2016-05-31 Rigel Pharmaceuticals, Inc. Carboxamide compounds and methods for using the same
US9062052B2 (en) 2008-04-23 2015-06-23 Rigel Pharmaceuticals, Inc. Carboxamide compounds and methods for using the same
US8871770B2 (en) 2008-04-23 2014-10-28 Rigel Pharmaceuticals Inc. Carboxamide compounds and methods for using the same
US8314107B2 (en) 2008-04-23 2012-11-20 Rigel Pharmaceuticals, Inc. Carboxamide compounds and methods for using the same
US9255085B2 (en) 2008-04-23 2016-02-09 Rigel Pharmaceuticals, Inc. Carboxamide compounds and methods for using the same
US9796664B2 (en) 2008-09-03 2017-10-24 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
US9265734B2 (en) 2008-09-03 2016-02-23 Biomarin Pharmaceutical Inc. Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
ES2350548A1 (es) * 2009-06-25 2011-01-25 Institut Univ. De Ciencia I Tecnologia, S.A. N-fenil-1-sulfonil-2-pirrolidinacarboxamidas para la identificacion de actividad biologica y farmacologica.
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US9512143B2 (en) 2011-02-28 2016-12-06 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US9540395B2 (en) 2011-02-28 2017-01-10 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10301323B2 (en) 2011-02-28 2019-05-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10280182B2 (en) 2011-02-28 2019-05-07 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10981933B2 (en) 2011-02-28 2021-04-20 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10526346B2 (en) 2011-02-28 2020-01-07 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US9908899B2 (en) 2011-02-28 2018-03-06 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
WO2014084330A1 (fr) * 2012-11-30 2014-06-05 協和発酵キリン株式会社 Composé hétérocyclique contenant de l'azote
US9701689B2 (en) 2012-11-30 2017-07-11 Kyowa Hakko Kirin Co., Ltd. Substituted pyridines and pyridazines as CCR10 receptor inhibitors
JPWO2014084330A1 (ja) * 2012-11-30 2017-01-05 協和発酵キリン株式会社 含窒素複素環化合物
CN104995173A (zh) * 2012-11-30 2015-10-21 协和发酵麒麟株式会社 含氮杂环化合物
US10029988B2 (en) 2013-03-15 2018-07-24 Biomarin Pharmaceutical Inc. HDAC inhibitors
US10428028B2 (en) 2013-03-15 2019-10-01 Biomarin Pharmaceutical Inc. HDAC inhibitors
USRE47193E1 (en) 2013-10-14 2019-01-08 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
US9663486B2 (en) 2013-10-14 2017-05-30 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
US10087174B2 (en) 2013-10-14 2018-10-02 Eisai R&D Management Co., Ltd. Selectively substituted quinoline compounds
US11866422B2 (en) 2016-06-21 2024-01-09 Orion Ophthalmology LLC Carbocyclic prolinamide derivatives
US11267803B2 (en) 2016-06-21 2022-03-08 Orion Ophthalmology LLC Carbocyclic prolinamide derivatives
US11377439B2 (en) 2016-06-21 2022-07-05 Orion Ophthalmology LLC Heterocyclic prolinamide derivatives
AU2019272538B2 (en) * 2018-05-22 2022-08-25 Orsobio, Inc. Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives
US11136290B2 (en) 2018-05-22 2021-10-05 The Liver Company Inc. Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives
JP2021524856A (ja) * 2018-05-22 2021-09-16 ギリアード サイエンシーズ， インコーポレイテッド スルフィニルアミノベンズアミドおよびスルホニルアミノベンズアミド誘導体
TWI732219B (zh) 2018-05-22 2021-07-01 美商基利科學股份有限公司 亞磺醯基胺基苯甲醯胺與磺醯基胺基苯甲醯胺之衍生物
CN112204008A (zh) * 2018-05-22 2021-01-08 吉利德科学公司 亚磺酰基氨基苯甲酰胺以及磺酰基氨基苯甲酰胺衍生物
JP7158500B2 (ja) 2018-05-22 2022-10-21 ザ リバー カンパニー インコーポレイテッド スルフィニルアミノベンズアミドおよびスルホニルアミノベンズアミド誘導体
WO2019226490A1 (fr) * 2018-05-22 2019-11-28 Gilead Sciences, Inc. Dérivés sulfinylaminobenzamide et sulfonylaminobenzamide
CN112204008B (zh) * 2018-05-22 2024-07-05 奥索生物公司 亚磺酰基氨基苯甲酰胺以及磺酰基氨基苯甲酰胺衍生物
US12049439B2 (en) 2018-05-22 2024-07-30 Orsobio, Inc. Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives
US11618747B2 (en) 2018-06-28 2023-04-04 Orsobio, Inc. LXR modulators with bicyclic core moiety
US11970484B2 (en) 2018-06-28 2024-04-30 Orsobio, Inc. LXR modulators with bicyclic core moiety
US12291523B2 (en) 2018-06-28 2025-05-06 Orsobio, Inc. LXR modulators with bicyclic core moiety

Also Published As

Publication number Publication date
AU2001280187A1 (en) 2002-03-13

Similar Documents

Publication Publication Date Title
WO2002018335A1 (fr) Derives d'amine cyclique
WO2001032654A3 (fr) Nouveaux composes heterocycliques et leur application a titre de medicaments
PT1178967E (pt) Derivados de quinolina como inibidores de enzimas mek
BR9205811A (pt) Derivados heterociclicos de aminas ciclicas
UA83243C2 (ru) Соединения, которые ингибируют натриезависимый переносчик глюкозы
BR0017010A (pt) Agentes antibacterianos 3-aminoquinazolin-2,4-diona
DK0976748T3 (da) Pyrrolidinderivater med phospholispase A2-hæmmende aktivitet
DE68920632D1 (de) Antiamnesische Pyrrolidin-Derivate.
ECSP055809A (es) Inhibidores 4-oxo-1-(3-fenil sustituido)-1,4-dihidro-1,8-naftiridina-3-carboxamida de la fosfodiesterasa-4
DK0445731T3 (da) Azabicyclo- og azacyclooxim- og -amin-choliner-giske midler og farmaceutisk acceptable salte deraf
DE69427517D1 (de) Tetracyclische kondensierte heterocyclische Verbindungen zur Behandlung von seniler Demenz
ES2126075T3 (es) Derivados biciclicos nitrogenados como inhibidores de la propil-endopeptidasa.
ATE210647T1 (de) Kondensierte piperin-derivate als stickstoffmonoxid-synthese-hemmer
GB2311780B (en) Pharmaceutical Piperazine Compounds
EP1044971A4 (fr) Derives de taxane
IL147445A0 (en) Taxane derivatives and processes for the preparation thereof
NZ517315A (en) New derivatives of A-500359
AU5566300A (en) Acylhydrazine derivatives, process for preparing the same and use thereof
ATE268329T1 (de) Aminomethylpyrrolidin-derivate mit aromatischen substituenten
HUP9901417A2 (hu) Új 2,3-benzodiazepin-származékok, előállításuk és alkalmazásuk gyógyszerként
ATE279191T1 (de) Trizyklische dihydrobenzofurane, verfahren zu deren herstellung und mittel
BG106048A (en) 6-[[(aryl and heteroaryl)oxy]methyl]naphthalene-2-carboximidamide derivatives, preparation and therapeutic application thereof
ATE286728T1 (de) Verwendung von homocysteinderivaten zur behandlung von bakteriellen infektionen
NO984547L (no) Nye oksazolidinderivater, fremgangsmÕte for deres fremstilling, samt legemidler inneholdende disse forbindelser
BR0115566A (pt) Compostos para emprego como inibidores de protease de hiv

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2002 523453

Kind code of ref document: A

Format of ref document f/p: F

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载